Related Experiment Videos
Effects of hydralazine on pregnant rats and their fetuses
P G Pryde1, E L Abel, J Hannigan
1Department of Obstetrics and Gynecology, Hulzel Hospital/Wayne State University School of Medicine, Detroit, Michigan.
Objective:
We conducted this study to assess potential teratogenic or fetotoxic effects of in utero hydralazine exposure in the rat.
Study Design:
Pregnant rats were treated with hydralazine (0, 15, or 30 mg/kg/day) by either gavage or subcutaneous injection during gestation days 8 through 19, inclusively. Surviving animals were killed, uterine contents examined, and fetuses evaluated by Wilson's method for teratologic examination.
Results:
Oral administration did not affect maternal weight gain or fetal or placental weights. Subcutaneous administration decreased fetal and placental weights but only in dams given the highest dose subcutaneously; significantly increased maternal mortality and reduced maternal weight gain were also observed. There was no increased incidence of fetal anomalies in any group.
Conclusion:
Hydralazine does not have teratogenic or fetopathic effects when given to rats in dosages that are nontoxic to the mother.